There are currently 60 clinical trials in Abilene, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including Retina Research Institute of Texas, Hendrick Medical Center and Retina Res Institute of Texas. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients
NCT04939090
Recruiting
This phase III trial compares the effects of olanzapine versus megestrol acetate in treating loss of appetite in patients with cancer that has spread to other places in the body (advanced). Olanzapine may stimulate and increase appetite. This study aims to find out if olanzapine is better than the usual approach (megestrol acetate) for stimulating appetite and preventing weight loss.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: Hendrick Medical Center, Abilene, Texas
Conditions: Advanced Malignant Solid Neoplasm, Anorexia, Hematopoietic and Lymphoid Cell Neoplasm
Register for Updates
Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration
NCT05904691
Recruiting
Multi-center, open-label, two-part safety assessment following administration of single ascending doses and repeat administration of the HTD of OCU-10-C-110 for Injection in the study eye of participants with nAMD
Gender:
ALL
Ages:
50 years and above
Trial Updated:
03/18/2025
Locations: Retina Research Institute of Texas, Abilene, Texas
Conditions: Neovascular Age-related Macular Degeneration (nAMD)
Register for Updates
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)
NCT04567550
Recruiting
ABBV-RGX-314 is being developed as a novel, potential one-time gene therapy treatment for the treatment of Diabetic Retinopathy (DR) with and without Center-Involved Diabetic Macular Edema (CI-DME). DR is a chronic and progressive complication of diabetes mellitus. It is a sight-threatening disease characterized in the early stages by neuronal and vascular dysfunction in the retina, and later by neovascularization that leads to further deterioration of functional vision. Despite the availability... Read More
Gender:
ALL
Ages:
Between 25 years and 89 years
Trial Updated:
03/14/2025
Locations: Retina Research Institute of Texas, LLC, Abilene, Texas
Conditions: Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME)
Register for Updates
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT03851445
Recruiting
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Hendrick Medical Center, Abilene, Texas
Conditions: Previously Treated Non-Small Cell Lung Cancer
Register for Updates
Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial
NCT05822583
Recruiting
COVID-19 can trigger a dysregulated immune response, and previous studies have shown that immune modulation can improve outcomes in hospitalized patients. This trial is designed to determine whether intensification of immune modulation early in the course of the disease (while patients are on low flow oxygen) with abatacept (active arm) combined with standard of care (SOC) improves recovery as compared with placebo + SOC (placebo arm). For both groups, intensification of immunomodulation will be... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: Hendrick Medical Center (Site 080-014), Abilene, Texas
Conditions: COVID-19
Register for Updates
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
NCT05949593
Recruiting
This Phase 3, multicenter, double-masked, parallel-group, placebo-controlled, randomized, fixed-dose clinical study is designed to evaluate the efficacy and safety of tinlarebant (LBS-008) in subjects diagnosed with GA.
Gender:
ALL
Ages:
Between 60 years and 85 years
Trial Updated:
02/12/2025
Locations: Belite Study Site, Abilene, Texas
Conditions: Geographic Atrophy
Register for Updates
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
NCT04704921
Recruiting
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-vascular endothelial growth factor (anti-VEGF)... Read More
Gender:
ALL
Ages:
Between 50 years and 89 years
Trial Updated:
01/27/2025
Locations: 144-West Texas Retina Consultants (WTRC) - Abilene Location, Abilene, Texas
Conditions: AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV, Neovascular AMD, Neovascular Age-related Macular Degeneration, Choroidal Neovascularization
Register for Updates
Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years
NCT05643534
Recruiting
This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of tenapanor (25 mg and 50 mg) in pediatric patients (≥12 and \<18 years old) with IBS-C when administered twice daily (BID) for 12 consecutive weeks.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
12/12/2024
Locations: Advance Clinical Trial PLLC, Abilene, Texas
Conditions: Irritable Bowel Syndrome With Constipation (IBS-C)
Register for Updates
Evaluation of the Bexa Breast Examination
NCT06643767
Recruiting
Objective: The "Bexa Breast Exam," or "BBE," for the purposes of this study is defined as the use of a Bexa device in conjunction with a portable, focused ultrasound examination to identify and further evaluate abnormal breast masses including cancer. Commercially, this combination of Bexa plus focused ultrasound is called "Bexa Breast ExamTM," and abbreviated as, "BBE." This study compares the Bexa Breast Exam (BBE) to the standard of care (digital breast tomosynthesis) in detecting masses and... Read More
Gender:
FEMALE
Ages:
Between 30 years and 75 years
Trial Updated:
10/16/2024
Locations: Hendrick Health - Vera West Women's Center, Abilene, Texas
Conditions: Breast Cancer
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Hendrick Medical Center, Abilene, Texas
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
Connect® Myeloid Disease Registry
NCT01688011
Recruiting
The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. This disease registry will also evaluate molecular and cellular markers that may provide further prognostic classification which may or may not be predictive of therapy and clinical outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: Hendrick Cancer Center, Abilene, Texas
Conditions: Myelodysplastic Syndromes, Primary Myelofibrosis, Leukemia, Myeloid, Acute
Register for Updates
Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study
NCT05797896
Recruiting
An observational study to investigate the natural history and evaluate biomarkers of participants with geographic atrophy secondary to age-related macular degeneration
Gender:
ALL
Ages:
65 years and above
Trial Updated:
04/08/2024
Locations: Retina Research Institute of Texas, Abilene, Texas
Conditions: Dry Age-related Macular Degeneration, Geographic Atrophy, Retinal Disease, Macular Degeneration, Macular Atrophy, Retinal Degeneration, Eye Diseases
Register for Updates